Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia
Metadatos
Mostrar el registro completo del ítemAutor
Plaza-Diaz, Julio; Ruiz Ojeda, Francisco Javier; López-Plaza, Bricia; Brandimonte-Hernández, Marco; Álvarez Mercado, Ana Isabel; Arcos-Castellanos, Lucía; Feliú-Batlle, Jaime; Hummel, Thomas; Palma-Milla, Samara; Gil Hernández, ÁngelEditorial
MDPI
Materia
cancer neoplasms dysgeusia
Fecha
2024-10-08Referencia bibliográfica
Plaza Díaz, J. et. al. Cancers 2024, 16, 3414. [https://doi.org/10.3390/cancers16193414]
Patrocinador
Medicinal Gardens S.L. through the Center for Industrial Technological Development (CDTI), “Cervera” Transfer R&D Projects. Ref. IDI-20210622. (Science and Education Ministry, Spain)Resumen
Background/Objectives: Dysgeusia contributes to the derangement of nutritional status
in patients with cancer as well as worsening the quality of life. There has been a lack of effective
treatments for taste disorders provided by the pharmaceutical industry. Methods: This was a pilot
randomized, parallel, triple-blind, and placebo-controlled intervention clinical trial in which 31 malnourished
patients with cancer and dysgeusia receiving antineoplastic treatment were randomized
into three arms [standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet)
or placebo (300 mg freeze-dried strawberry)] for three months. Patients consumed a DMB or placebo tablet before each main meal. Using the nanopore methodology, we analyzed the oral microbiome
of patients with cancer using saliva samples. Results: All patients with cancer and dysgeusia had
dysbiosis in terms of lower bacterial diversity and richness. DMB consumption was associated with
changes in oral microbiome composition. Neither selected bacteria nor taste perception, type of diet,
and cytokine levels were associated with mucositis. Likewise, alcohol and tobacco consumption
as well as general and digestive toxicity due to systemic therapy were not associated with specific
changes of the oral microbiome, according to logistic binary regression. The standard dose of DMB
resulted in a lower abundance of Veillonella compared with the high DMB dose and placebo at
3 months after intervention with DMB. In particular, some species such as Streptococcus parasanguinis,
Veillonella parvula, and Streptococcus mutans were less abundant in the DMB standard-dose group.
Additionally, the consumption of a standard dose of DMB revealed a negative association between the
concentrations of TNF-α and the abundance of species such as Streptococcus thermophilus, Streptococcus
pneumoniae, Streptococcus dysgalactiae and Streptococcus agalactiae. Conclusions: Accordingly, regular
DMB consumption could modify the oral microbiome in patients with cancer and dysgeusia, which
may contribute to maintaining an appropriate immune response. However, as the present pilot study
involved a small number of participants, further studies are necessary to draw robust conclusions
from the data.